Description

• Title:
  DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
• Creator:
  Abram, Kamila;
  Banaś, Patryk;
  Adamus, Justyna;
  Pierzchała, Jakub Rafał;
  Bednarz, Katarzyna;
  Sobańska, Natalia;
  Banasiak, Aleksandra Paulina;
  Teichman, Rafał;
  Kasprowicz, Jakub;
  Hyjek, Michał
• Description:
  Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direct-acting antivirals ( DAAs) for the treatment of chronic HCV, sustained virological response (SVR) rates have begun to increase, even in treatment-resistant cases. Studies have also shown that DAAs may have applications in other viral diseases and even In the treatment of breast cancer.   Aim of the study The purpouse of our study was to review scientific articles to show the efficiency and potential use of DAAs in the treatment of chronic HCV, and to identify possible directions for further research.   Methods and materials We reviewed the English literature in the PubMed, using the key words: "simeprevir" ; "sofosbuvir" ; "velpatasvir" ; "telaprevir" ; "chronic hepatitis C".   Results Studies have shown that the therapeutic regimens currently being designed with (DAAs) offer the possibility of treating almost the entire population with hepatitis C, while reducing side effects of interferon therapy such as increased AST, ALT activities, diarrhoea, vomiting, nausea and  depression. They remain effective and tolerable, regardless of the stage of cirrhosis and associated serious co-morbidities. Analysis of studiem shows, that DAAs also show efficacy against other disease such as breast cancer, MRSA infections, SARS-CoV-2 or flavivirus infection.   Conclusion All (DAAs) are effective in the treatment of patients with HCV, including cirrhosis. They result in significant improvements in prognosis and clinical outcomes. Promising results have been obtained in published data on the effect of DAAs against disease entities other than HCV, suggesting the rationale for future clinical trials to further the hypothesis of the increased potential of these drugs.
• Object availability:
  free access
• Rights:
  Prawa autorskie (c) 2023 Kamila Abram, Patryk Banaś, Justyna Adamus, Jakub Rafał Pierzchała, Katarzyna Bednarz, Natalia Sobańska, Aleksandra Paulina Banasiak, Rafał Teichman, Jakub Kasprowicz, Michał Hyjek;
  https://creativecommons.org/licenses/by-nc-sa/4.0
• Date:
  2023.02.02
• Type:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Language:
  English
• Source:
  Journal of Education, Health and Sport; Vol. 13 No. 3 (2023); 200-206;
  Journal of Education, Health and Sport; Tom 13 Nr 3 (2023); 200-206;
  2391-8306
• Format:
  application/pdf
• Publisher:
  Nicolaus Copernicus University, Toruń, Poland
• Relation: https://apcz.umk.pl/JEHS/article/view/41811/34697
• Subject:
  simeprevir;
  sofosbuvir;
  velpatasvir;
  telaprevir;
  chronic hepatitis C
• Identifier: https://apcz.umk.pl/JEHS/article/view/41811
• Data provider:
  Akademicka Platforma Czasopism
• Can I use it?:
  seek permission
• Type:
  text